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Abstract
Background:  Patients with Alzheimer's disease experience a progressive loss of cognitive
function, and the ability to independently perform activities of daily life. Sometimes a dependent
stage is reached quite early in the disease, when caregivers decide that the patients can no longer
be left alone safely. This is an important aspect of Alzheimer's for patients, their families, and also
health care providers. Understanding the relationship between a patient's current cognitive status
and their need for care may assist clinicians when recommending an appropriate management plan.
In this study, we investigated the relationship of cognitive function to dependence on caregivers
before the patients reach a severe stage of the disease.
Methods: Data were obtained on 1,289 patients with mild-to-moderate Alzheimer's disease
studied in two randomised clinical trials of galantamine (Reminyl®). Cognition was assessed using
the cognitive part of the Alzheimer's Disease Assessment Scale (ADAS-cog) and Mini-Mental State
Examination (MMSE). Patients were considered dependent if they required >12 hours of
supervision each day or had high care needs. The Disability Assessment for Dementia (DAD) scale
was also used as a measure of dependence. Disability was predicted directly using MMSE and
ADAS-cog and compared to predictions from converted scores.
Results: The odds ratio of dependence was significantly higher amongst the patients with worse
cognitive impairment, adjusting for age, gender and antipsychotic medication use. For example, a 4-
point difference in ADAS-cog score was associated with an increase of 17% (95% CI 11–23) in the
adjusted odds for >12 hours of supervision, and of 35% (95% CI 28–43) for dependence. Disability
predicted directly using actual ADAS-cog and scores converted from MMSE values had close
agreement using the models developed.
Conclusion: In patients with mild-to-moderate Alzheimer's disease, even relatively small degrees
of poorer cognitive function increased the risk of losing the ability to live independently.
Background
Patients with Alzheimer's disease experience a progressive
cognitive loss leading to increasingly shorter periods dur-
ing which they can safely be left alone and to dependence
Published: 19 August 2002
BMC Neurology 2002, 2:6
Received: 5 April 2002
Accepted: 19 August 2002
This article is available from: http://www.biomedcentral.com/1471-2377/2/6
© 2002 Caro et al; licensee BioMed Central Ltd. This article is published in Open Access: verbatim copying and redistribution of this article are permitted 
in all media for any non-commercial purpose, provided this notice is preserved along with the article's original URL.BMC Neurology 2002, 2 http://www.biomedcentral.com/1471-2377/2/6
Page 2 of 7
(page number not for citation purposes)
on their caregivers for help with the activities of daily life
[1–5]. The Mini-Mental State Examination (MMSE) [6] is
commonly used in clinical practice to assess cognition,
whereas in research, the cognitive part of the Alzheimer's
Disease Assessment Scale (ADAS-cog) [7] predominates.
There is, therefore, interest in how cognitive function ob-
served for patients in clinical trials compares with the re-
sults from clinical practice and the likely effects on
patients' wider functioning [8].
In this study, we investigated the relationship of patients'
cognitive function to dependence on caregivers before the
patients reach a severe stage of the disease. Cognitive func-
tion was assessed with both the ADAS-cog and the MMSE.
Our analyses employed three different definitions of de-
pendence. In one approach, caregivers assessed the
number of hours of supervision patients required each
day, in another patients were assigned a level of depend-
ence based on their care needs [9], and in the third, car-
egivers were asked questions about the patients' ability to
independently perform activities of daily living that had
been attempted in the preceding two weeks [10].
In a clinical setting, MMSE scores are frequently available,
and conversions of cognitive scale scores from one to the
other have been proposed [11,12]. One aspect of this
study evaluates whether it is reasonable to convert MMSE
to ADAS-cog and predict dependence based on the con-
verted score. The reasonableness of doing this is judged
based on how similar the results are to what would be ob-
tained if a subject's actual ADAS-cog score were known.
Methods
Data sources
Data were obtained on 1,289 patients diagnosed with
mild-to-moderate Alzheimer's disease studied in two ran-
domised clinical trials of galantamine (Reminyl®) [13,14].
This is a post-hoc analysis employing data obtained from
patients' baseline visits, before they began treatment in
the trials. All patients enrolled in these trials were diag-
nosed with Alzheimer's disease according to NINCDS-
ADRDA classification [15]. The patients had a mild-to-
moderate disease (MMSE scores 10–24) with a history of
cognitive decline, gradual onset, and progressive disease
over a period of at least six months. Cognitive function
was assessed using both the ADAS-cog and MMSE scales.
Caregivers of the patients included in these analyses
agreed to participate in the trial.
Dependence
Dependence was measured using three definitions de-
rived from the hours of supervision needed from a car-
egiver, the amount of care needed and the patient's ability
to carry out the activities of daily life.
The caregivers were asked to assess whether the patient re-
quired 24-hour supervision, and if this was not consid-
ered necessary, caregivers reported the number of hours
the patient could be left alone each day. From these data,
the amount of supervision time required by a patient dur-
ing the course of a day was derived. Patients were consid-
ered to have become dependent on caregivers if the
caregivers reported that they required more than twelve
hours of supervision each day.
Patients' care needs were recorded using an instrument
that was developed and validated specifically to assess de-
pendency of patients with Alzheimer's disease [9]. This
dependence scale was designed to assess levels of need
and therefore the care expected to be required, as a result
of the loss of cognitive and functional skills typically ob-
served in patients with Alzheimer's disease. Each caregiver
was asked thirteen questions about the type of care the pa-
tient required. Depending on the responses, patients were
assigned to one of six levels of dependency, with level zero
representing independence and level five the highest level
of dependence. Items in level three and above indicate
that patients need supervision and assistance with com-
mon tasks, for example they need to be watched when
awake, or escorted when outside, or accompanied when
bathing and eating. Patients assigned to dependency lev-
els of three or higher were considered to be dependent.
The Disability Assessment for Dementia (DAD) scale was
also completed by the caregivers [10]. This instrument
was developed and validated to measure the functional
disability of patients with Alzheimer's disease. Caregivers
answered questions about the patients' ability to inde-
pendently perform both instrumental and basic activities
of daily living that had been attempted in the preceding
two weeks. The proportion of DAD activities successfully
completed out of those attempted is then determined and
reported as a percentage.
Analyses
Analyses were conducted separately for each measure of
dependence. In addition to the two measures of cognitive
functioning, age, gender, time since onset of cognitive
problems, use of antipsychotic medication, presence of
extrapyramidal symptoms, and living situation were con-
sidered as potential predictors. Since the MMSE and
ADAS-cog are correlated, separate models were construct-
ed for each of the outcomes using each cognitive scale
alone.
The relation of the two dichotomous dependence out-
comes (>12 hours supervision and dependence level>=3)
to potential predictors, including cognitive function, was
investigated initially in bivariate analyses. For continuous
predictors such as MMSE and ADAS-cog scores, linearityBMC Neurology 2002, 2 http://www.biomedcentral.com/1471-2377/2/6
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in the log of the odds of the outcomes was verified over
subintervals of the predictors. For categorical predictors
such as gender, the odds ratio was computed and tested
for significance. The significant predictors were retained
and included in a logistic regression model to estimate the
odds ratio for being defined as dependent, and to measure
the effect of cognitive function, adjusting for other factors.
A stepwise forward procedure was used to identify the
most important predictors.
Due to a skewed spread of DAD scores over its range, a
transformation was required to normalize the distribu-
tion. Since the DAD is scored as a proportion, the recom-
mended transformation is arcsin (square root (DAD)).
The relation of the transformed DAD scores to the predic-
tors was determined using correlation coefficients, t-tests
and ANOVAs. Predictors were retained in two multivariate
regression models to investigate the relation of the trans-
formed DAD score to either MMSE or ADAS-cog score and
other determinants. A stepwise forward procedure was
used to identify statistically significant predictors.
We then used these models to investigate how well MMSE
values converted to ADAS-cog predict dependence com-
pared to predictions based on the actual ADAS-cog values,
after adjusting for other factors. The MMSE scores were
converted linearly to ADAS-cog values (a decrease of 1
MMSE = an increase of 2.33 ADAS-cog points, or ADAS-
cog = 70-2.33*MMSE). For each patient, the DAD score
was then predicted based on the actual and converted
ADAS-cog scores. The difference between the two predic-
tions was used as the measure of agreement. The predicted
DAD scores were then compared to each other.
Results
The socio-demographic and clinical characteristics of the
1,287 patients included in these analyses are summarized
in Table 1. Two patients were excluded from the analyses
because their MMSE score was reported as zero. On aver-
age, caregivers reported that their patients required about
14 hours of supervision each day (SD 9.3). There was con-
siderable variation in the responses, as 25% (N = 326)
were reported to require no supervision while 15% (N =
188) were felt to require 24-hour supervision. Approxi-
mately two-thirds required more than 12 hours of super-
vision, and their mean ADAS-cog, MMSE, and DAD
scores, were significantly worse than those of patients who
were deemed less dependent.
Table 1: Characteristics of patients at the time of enrollment in the trials
Characteristic All Patients Supervision per day Dependence Level
≤  12 hrs > 12 hrs < 3 ≥  3
Number 1287 407 880 692 595
Socio-demographic details
Age, (years) Mean 
(SD)
73.8 (8.3) 72.9 (8.5) 74.2 (8.2)* 72.1 (8.6) 75.8 (7.5)*
Female N (%) 801 (62) 261 (64.1) 540 (61.4) 388 (56.1) 413 (69.4)*
Education beyond elementary school N (%) 876 (68.8) 271 (67.6) 605 (69.3) 508 (74.1) 368 (62.6)*
Lives with caregiver N (%) 934 (74.2) 203 (51.5) 731 (84.5)* 496 (73.0) 438 (75.5)
Spouse or partner caregiver N (%) 781 (62.1) 175 (43.0) 606 (68.9)* 431 (62.3) 350 (58.8)
Clinical characteristics
Time since onset of cognitive problems, 
(years)
Mean 
(SD)
3.8 (2.6) 3.6 (2.6) 3.9 (2.6)* 3.7 (2.6) 4.0 (2.6)*
Time since AD diagnosis (years) Mean 
(SD)
1.0 (1.4) 0.9 (1.2) 1.1 (1.4) 0.9 (1.3) 1.1 (1.4)*
Extra-pyramidal symptoms N (%) 68 (5.2) 15 (3.7) 53 (6.0) 29 (4.2) 39 (6.6)
Anti-psychotic medication N (%) 328 (25.5) 81 (19.9) 247 (28.1)* 134 (19.3) 194 (32.6)*
MMSE Mean 
(SD)
19.3 (3.7) 20.4 (3.4) 18.8 (3.8)* 20.5 (3.3) 18.0 (3.8)*
ADAS-cog Mean 
(SD)
25.4 (10.4) 22.7 (9.7) 26.7 (10.5)* 22.0 (8.7) 29.5 (10.8)*
Dependence
Dependence level >= 3 N (%) 583 (46.0) 134 (32.9) 461 (52.4)
DAD Mean 
(SD)
70.1 (22.5) 77.7 (20.0) 66.7 (22.7)* 81.9 (14.9) 56.3 (22.0)*
* Statistically significant difference between groups (p = 0.05).BMC Neurology 2002, 2 http://www.biomedcentral.com/1471-2377/2/6
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Overall, 46% of patients were assigned to the dependent
care levels > = 3, and their mean DAD score was signifi-
cantly lower than that of those who were less dependent
(56% vs. 82%, t-test p < 0.0001). Antipsychotic medica-
tion was prescribed to 26% of the patients and they too
had DAD scores lower than patients not prescribed antip-
sychotic medication (64% vs. 72%, t-test, p-value <
0.001). Far fewer patients overall had extrapyramidal
symptoms, however, among those that did, the mean
DAD score was lower than for those without symptoms
(62% vs 70%, t-test, p-value 0.0037).
The odds ratio for both categorical measures of depend-
ence was significantly higher with worse cognitive impair-
ment, increasing with each detrimental point change in
ADAS-cog or MMSE score, adjusting for age, gender and
use of antipsychotic medication (Table 2). For the MMSE
model, a one-point difference was associated with an in-
crease in the adjusted odds for requiring >12 hours super-
vision per day of 13% (95% CI 9–17) and for dependence
level > = 3 of 22% (95% CI 18–27). A one-point differ-
ence of the ADAS-cog score was associated with an in-
crease in the adjusted odds for requiring >12 hours
supervision per day of 4% (95% CI 3–5) and for depend-
ence level > = 3 of 8% (95% CI 6–9), after adjusting for
age, gender and use of antipsychotic medication.
For predictions of dependence based on transformed
scores from the DAD two separate models were devel-
oped. One model was based on the ADAS-cog and the sec-
ond on the MMSE (Table 3). In each case, the cognitive
score was found to be a strong predictor of dependence.
No significant interaction was present.
Disability predicted directly using the actual ADAS-cog
scores and other patient characteristics was compared to
prediction based on ADAS-cog scores converted from
MMSE scores, adjusting for other patient characteristics.
Figure 1 shows a summary of these predictions. For MMSE
scores ranging from 10 to 24, we calculated the average
predicted DAD using the actual ADAS-cog scores (with
standard deviation); the corresponding values for the pre-
dictions with converted values are also shown. There was
a close agreement between the average predictions. For ex-
ample, our sample contained 91 subjects with baseline
MMSE score of 20; the average ADAS-cog score for these
patients was 24.2, which is reasonably close to the con-
verted value of 23.4. The average DAD score predicted
from the actual ADAS-cog scores was 74% with a standard
deviation of 10%. The average of predictions made with
converted scores and other patient's characteristics was
76% (SD = 4.9%), for a difference of 1.4%. Similarly, the
average difference in predictions for other MMSE scores
were also reasonably small, ranging from -1.5% to 3.1%,
equivalent to less than a single activity on the DAD.
Discussion
The loss of a patient's ability to independently perform
daily activities is an important aspect of Alzheimer's for
patients and their families, and for health care decision-
makers. Our study has demonstrated that relatively small
degrees of loss of cognitive skills in patients at the mild-
to-moderate stages of the disease leads to an increased risk
of losing the ability to live independently. In our study of
patients recruited for clinical trials at the mild-to-moder-
ate stage, 69% already required more than 12 hours of su-
pervision per day. This is consistent with other studies,
which have shown that sometimes a dependent stage is
reached quite early in the disease, when caregivers decide
that the patients can no longer be left alone safely
[3,16,17].
A three-point difference in MMSE score was associated
with an increase in the adjusted odds of requiring more
than 12 hours of supervision of 43% at the time of the as-
sessment; and if dependence is measured as level three or
Table 2: Odds ratios (95% CI) for dependence
Characteristic MMSE Model ADAS-cog Model
Supervision Time Dependence Level Supervision Time Dependence Level
-2log(L) 1538.9 1524.5 1509.8 1491.1
Age (years) 1.02 (1.00–1.03) 1.06 (1.04–1.08) 1.02 (1.00–1.03) 1.05 (1.04–1.07)
Male vs. female 1.29 (1.00–1.66) 0.66 (0.52–0.86) 1.34 (1.04–1.74) 0.70 (0.54–0.90)
Anti-psychotic medication use 1.55 (1.16–2.07) 1.95 (1.47–2.58) 1.51 (1.13–2.03) 1.89 (1.42–2.51)
MMSE 0.89 (0.86–0.92) 0.82 (0.79–0.85) - -
ADAS-cog - - 1.04 (1.03–1.05) 1.08 (1.06–1.09)BMC Neurology 2002, 2 http://www.biomedcentral.com/1471-2377/2/6
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higher, the odds increase by 82%, even after adjusting for
age, gender and use of antipsychotic medication. Similar-
ly, a 4-point difference in ADAS-cog score is associated
with an increase in the adjusted odds for requiring more
than 12 hours of supervision of 17%, and 35% for having
a dependence level greater than two. The very comprehen-
sive measures of dependence collected at the start of these
trials allowed us to evaluate the association of depend-
ence with a patient's cognitive functioning at that point in
time. It is important to note that since this is a cross-sec-
tional study we could not investigate the extent to which
decreases or improvements in cognitive function would
be associated with changes in dependence over time.
Behavioral disturbances are common amongst patients
with Alzheimer's disease [18] and antipsychotic medica-
tions were prescribed for about one-quarter of the patients
in our study. Antipsychotic medication use was also con-
sistently found to be a predictor of having an increased
risk of disability, regardless of how dependence was meas-
ured. This is consistent with other studies, which found
that patients using antipsychotic agents [19] or displaying
psychotic symptoms [1,19–21] are more likely to experi-
ence a faster functional decline. Very few patients in our
study had extra-pyramidal symptoms; it is therefore diffi-
cult to interpret their meaning with certainty. Other pub-
lished studies however, have linked these symptoms with
greater functional decline [1,20,21].
One limitation of this study is that these data were collect-
ed from patients enrolled in clinical trials, and therefore
our sample may not be representative of patients routine-
ly treated in clinical practice. Nevertheless, these data pro-
vide a unique opportunity for analyses as information was
collected using both the MMSE and ADAS-cog scales, and
three measures of dependence.
Both the instruments used to measure dependence in this
study had been developed and validated specifically for
use in patients with Alzheimer's disease [9,10]. The de-
Figure 1
Mean predictions of DAD scores based on actual and converted ADAS-cog scores.
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pendence scale was designed to assess the care needs of
patients and the DAD scale to measure functional disabil-
ity. Both instruments were developed to avoid some of the
common problems observed with other measures of func-
tional decline, such as whether certain instrumental activ-
ities of daily living had ever been performed by the patient
[23]. Our results were consistent between the models as
the same predictors of dependence were found to be im-
portant regardless of how dependence was measured.
The MMSE is convenient to administer and practical to
use during a routine clinic visit, but clinical trials conduct-
ed to study treatments for Alzheimer's disease have prima-
rily used ADAS-cog as the measure of cognition. This
study indicates that it is reasonable to convert MMSE to
ADAS-cog and predict dependence based on the convert-
ed score. Our study suggests, that in clinical practice a con-
version that assumes one MMSE point is equivalent to
2.33 ADAS-cog points (or ADAS-cog = 70-2.33*MMSE)
will yield a reasonably accurate estimate of disability for
patients at the mild-to-moderate stages. This is also con-
sistent with the findings in another study (ADAS-cog =
72.2-2.41*MMSE) [11]. If its relation to dependence is the
main reason to measure cognition, then clinicians can be
reassured about these conversions.
Conclusions
In our study, patients who had relatively small degrees of
greater loss of cognitive function, whether measured using
either the ADAS-cog or MMSE, did appear to be at in-
creased risk of being dependent on caregivers. Under-
standing the relationship between a patient's current
cognitive status, current therapies and their need for care
may assist clinicians in the management of patients diag-
nosed with Alzheimer's disease. Moreover, this informa-
tion can facilitate discussions and planning with
caregivers. Future studies conducted to evaluate these rela-
tionships longitudinally can further inform our under-
standing of the relationship between cognitive function
and dependence.
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Table 3: Parameter estimates for models for the relationship between transformed DAD score and cognitive function
MMSE Model ADAS Model
Parameter Estimate 
(SE)
P-Value Parameter Estimate 
(SE)
P-Value
Model R2 0.29 0.32
Intercept 0.902 (0.080) < 0.0001 1.870 (0.067) < 0.0001
Age -0.006 (0.001) < 0.0001 -0.005 (0.001) < 0.0001
Male vs. Female -0.025 (0.015) 0.099 -0.034 (0.015) 0.023
Time since onset (years) -0.009 (0.003) 0.001 -0.007 (0.003) 0.013
Anti-psychotic medication use -0.078 (0.016) < 0.0001 -0.074 (0.016) < 0.0001
Lives with caregiver -0.071 (0.017) < 0.0001 -0.069 (0.016) < 0.0001
MMSE 0.036 (0.002) < 0.0001 - -
ADAS-cog - - 0.014 (0.001) < 0.0001
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